摘要
【目的】研究核苷类药物治疗失代偿期乙型、丁型重叠感染肝炎肝硬化48周的临床疗效。【方法】24例失代偿期乙型、丁型重叠感染肝炎肝硬化患者在内科综合治疗基础上口服拉米夫定100mg每日1次。疗程中监测患者生化学指标（ALT、AST、TBil、ALB）、凝血功能（凝血酶原时间PT）、HBsAg定量、child—push评分，B超门静脉宽度、门静脉峰值流速均有不同程度的改善。并观察有无不良反应的发生。【结果】24例患者各项指标得到明显改善，疗程中无明显不良反应发生。【结论】拉米夫定治疗失代偿期乙型、丁型重叠感染肝炎肝硬化患者有较好生化学指标改善、HBsAg下降及抗HBV病毒学应答，部分患者抗HDV病毒学应答。
[Objective]To investigate the clinical efficacy of nucleoside analogues for the treatment of de- compensated liver cirrhosis caused by chronic hepatitis B and D virus （HBV and HDV） co-infection. [Methods] A total of 21 patients with liver cirrhosis caused by chronic HBV and HDV co-infection were given nucleoside analogues（lamivudine 100mg, qd, adefovir 10rag, qd or entecavir 0. 5rag, qd） based on internal medicine treatment. Biochemical indexes, coagulation function, Child-Pugh scores, portal vein width, portal vein peak flow rate and HBsAg were monitoring during the therapy. Adverse reactions were observed. [Results]All parameters in 21 patients were improved obviously. No adverse reaction occurred during the ther- apy. [Conclusion] Nucleoside drugs for the treatment of patients with the decompensated cirrhosis caused by the co-infection of HBV and HDV can improve biomedical markers and reduce HBsAg, anti-HBV virology re- sponse and anti-HDV virology response of some patients.
出处
《医学临床研究》
CAS
2013年第11期2174-2176,共3页
Journal of Clinical Research
关键词
肝炎
乙型
肝炎
丁型
肝硬化
核苷酸类
Hepatitis B
Hepatitis D
Liver Cirrhosis
Nucleotides
